Teva Pharmaceutical Industries Limited's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the second quarter 2026 to a ratio of 3.92, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the second quarter 2026. Average collection period, for Teva Pharmaceutical Industries Limited's accounts receivable remained unchanged at 93 days, in the Jun 30 2026 quarter.

If we take a look into Healthcare sector 438 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 2885 to 2937.

What is Receivable Turnover Ratio?
What is Teva Pharmaceutical Industries Limited Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

TEVA Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	-1.99 %	0.27 %	492.49 %	10.05 %	-5.36 %
Y / Y Revenue Change	-0.81 %	2.36 %	-64.55 %	3.44 %	0.29 %
Receivable Turnover Ratio (TTM)	3.92	3.91	3.88	5.9	6.03
TEVA's Total Ranking	# 2937	# 2885	# 1980	# 1995	# 2403
Accounts Receivable average collection period days	93	93	94	62	61
Seq. Receivable Change	2.95 %	-8.52 %	-2.65 %	6.9 %	5.32 %
Seq. Revenue Change	3.99 %	165.53 %	-66.52 %	7.28 %	7.32 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 132
Healthcare Sector	# 439
Overall Market	# 2937

Receivable Turnover Ratio Statistics
High	Average	Low
6.03	3.78	3.07
(Jun 30 2025)		(Dec 31 2017)

TEVA Company Profile • Back to TEVA Efficiency Comparisons • Compare TEVA Receivables Turnover Ratio to its Competitors

Financial Statements
Teva Pharmaceutical Industries Limited's Accounts Receivable	$ 3,493 Millions	Visit TEVA's Balance sheet
Teva Pharmaceutical Industries Limited's Sales TTM	$ 14,105 Millions	Visit TEVA's Income Statement
Sources of TEVA's Revenues		Visit TEVA's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
TEVA's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
TEVA's Growth Rates	TEVA's Roa	TEVA's Inventory Turnover Ratio	TEVA's Dividend Comparisons
TEVA's Profitability Ratios	TEVA's Roi	TEVA's Asset Turnover Ratio	TEVA's Dividend Growth
TEVA's Valuation Ratios	TEVA's Roe	TEVA's Financial Strength Ratios	TEVA's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Veracyte Inc	11.07	$ 544.735 Millions	$ 49.194 Millions
International Stem Cell Corporation	10.91	$ 9.514 Millions	$ 0.872 Millions
Premier Air Charter Holdings Inc	10.66	$ 31.562 Millions	$ 2.961 Millions
C4 Therapeutics Inc	10.65	$ 35.039 Millions	$ 3.290 Millions
Kymera Therapeutics Inc	10.50	$ 105.000 Millions	$ 10.000 Millions
Lifeloc Technologies Inc	10.48	$ 9.269 Millions	$ 0.884 Millions
Irhythm Holdings Inc	10.32	$ 825.702 Millions	$ 80.007 Millions
Immucell Corporation	10.29	$ 29.777 Millions	$ 2.893 Millions
Addus Homecare Corp	10.23	$ 1,475.610 Millions	$ 144.195 Millions
Dariohealth Corp	10.23	$ 21.196 Millions	$ 2.072 Millions
Biodesix Inc	10.21	$ 102.939 Millions	$ 10.081 Millions
Radnet Inc	10.11	$ 2,268.932 Millions	$ 224.447 Millions
Utah Medical Products Inc	9.88	$ 35.679 Millions	$ 3.612 Millions
Lensar Inc	9.75	$ 60.264 Millions	$ 6.184 Millions
Biolife Solutions Inc	9.67	$ 102.718 Millions	$ 10.626 Millions
Encompass Health Corporation	9.57	$ 6,206.100 Millions	$ 648.325 Millions
The Oncology Institute Inc	9.57	$ 587.244 Millions	$ 61.364 Millions
Alumis inc	9.44	$ 7.398 Millions	$ 0.784 Millions
Enanta Pharmaceuticals Inc	9.29	$ 65.258 Millions	$ 7.027 Millions
Neuronetics Inc	9.24	$ 154.594 Millions	$ 16.732 Millions
Myomo Inc	9.24	$ 44.242 Millions	$ 4.790 Millions
Harmony Biosciences Holdings inc	9.22	$ 960.191 Millions	$ 104.164 Millions
Pavmed Inc	9.16	$ 0.126 Millions	$ 0.014 Millions
Ardent Health Inc	9.16	$ 6,405.940 Millions	$ 699.363 Millions
The Pennant Group Inc	9.15	$ 1,101.710 Millions	$ 120.457 Millions
Lexicon Pharmaceuticals Inc	9.14	$ 41.469 Millions	$ 4.535 Millions
Bioaffinity Technologies Inc	9.11	$ 5.901 Millions	$ 0.648 Millions
Nuvation Bio Inc	9.05	$ 169.551 Millions	$ 18.737 Millions
Sunshine Biopharma Inc	9.03	$ 35.347 Millions	$ 3.916 Millions
Biocryst Pharmaceuticals Inc	9.00	$ 940.613 Millions	$ 104.543 Millions

Date modified: 2026-08-12T20:54:13+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.